Copyright
©The Author(s) 2022.
World J Clin Oncol. Sep 24, 2022; 13(9): 758-761
Published online Sep 24, 2022. doi: 10.5306/wjco.v13.i9.758
Published online Sep 24, 2022. doi: 10.5306/wjco.v13.i9.758
Adjuvant NSCLC | ||||
Study | IO agent | Strategy | Objective | Status |
Impower-010[7] | Atezolizumab (anti-PD-L1) | IO mono | OS in selected PD-L1 population | FDA approved in II-IIIA NSCLC PD-L1+ |
KeyNote-091 (PEARLS)[8] | Pembrolizumab (anti-PD-L1) | IO mono | DFS | Interim analysis: positive in IB-IIIA NSCLC all corners |
ANVIL[9] | Nivolumab (anti-PD1) | IO mono | OS and DFS | Active, not recruiting |
NADIM-Adjuvant[10] | Nivolumab (anti-PD-1) | ChT + IO | DFS | Recruiting |
Mermaid-1[11] | Durvalumab (anti-PD-L1) | ChT + IO | DFS in MRD+ | Recruiting |
- Citation: Aguado C, Maestre UJ, Mielgo-Rubio X. Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing—and fast. World J Clin Oncol 2022; 13(9): 758-761
- URL: https://www.wjgnet.com/2218-4333/full/v13/i9/758.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i9.758